An Open-label, Randomized, Single-dose Crossover Study to Evaluate the Pharmacokinetics, Safety and Tolerability of IN-C009 in Healthy Subjects
Latest Information Update: 08 Oct 2021
At a glance
- Drugs Dapagliflozin (Primary) ; Dapagliflozin/linagliptin (Primary) ; Linagliptin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Pharmacokinetics
Most Recent Events
- 08 Oct 2021 New trial record